The earnings call presented a mixed picture with notable achievements in Consumer Care and cash flow, but challenges in sales decline and price/mix headwinds were evident. The positive start to 2025 and strategic investments provide a cautiously optimistic outlook.

Company Guidance -

Q2 2025

During the call, Croda provided guidance on its fiscal year 2024 performance, highlighting several key metrics. Group sales were reported at £1.6 billion, declining by 4% on a reported basis or 1% at constant currency. Adjusted operating profit decreased by 13% to £280 million. Profit before tax (PBT) was within the guidance range at £273 million or £260 million on a reported basis. The company maintained a strong cash flow with free cash flow up over 9% to £181 million. Divisional performance varied, with Consumer Care sales up 7% in constant currency and Industrial Specialties up 2%, while Life Sciences sales declined by 6%. Croda expects 2025 to start well with good revenue growth, anticipating Consumer Care and Life Sciences to grow, while Industrial Specialties remains flat. For 2025, the company projects group adjusted PBT to be between £265 million and £295 million at constant currency.

Consumer Care Growth

Consumer Care sales grew by 7% in constant currency, with local and regional customer sales up by 11%, driven by strong demand and innovation.

Operating Margin Improvement

Operating margin improved from 16.6% in the first half to 17.7% in the second half, aided by higher sales volumes and cost control measures.

Strong Cash Flow

Free cash flow increased to £181 million, up over 9%, with strong working capital discipline and reduced capital expenditure.

Positive Start to 2025

2025 began with good revenue growth across all businesses and markets, indicating a positive outlook.

Pharma Investment

Continued strategic investments in pharma, including new facilities in the US and Europe, positioning for future growth.

Croda International (GB:49GP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:49GP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 29, 2025	2025 (Q2)	- / -	―	―	―	―
Feb 25, 2025	2024 (Q4)	- / -	―	―	―	―
Jul 30, 2024	2024 (Q2)	- / -	―	―	―	―
Feb 27, 2024	2023 (Q4)	- / -	―	―	―	―
Jul 25, 2023	2023 (Q2)	- / -	―	―	―	―
Feb 28, 2023	2022 (Q4)	- / -	―	―	―	―
Jul 29, 2022	2022 (Q2)	- / -	―	―	―	―
Mar 01, 2022	2021 (Q4)	- / -	―	―	―	―
Jul 27, 2021	2021 (Q2)	- / -	―	―	―	―
Mar 02, 2021	2020 (Q4)	- / -	―	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:49GP Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 25, 2025	86.57p	86.57p	0.00%
Jul 30, 2024	81.14p	81.14p	0.00%
Feb 27, 2024	77.08p	77.08p	0.00%
Jul 25, 2023	83.22p	83.22p	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Croda International (49GP) (GB:49GP) report earnings?

Croda International (49GP) (GB:49GP) is schdueled to report earning on Jul 29, 2025, TBA (Not Confirmed).

What is Croda International (49GP) (GB:49GP) earnings time?

Croda International (49GP) (GB:49GP) earnings time is at Jul 29, 2025, TBA (Not Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Croda International (49GP) stock?

The P/E ratio of Croda International is N/A.

What is GB:49GP EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing